Trevi Therapeutics Inc (NASDAQ:TRVI) price on Thursday, March 20, fall -2.94% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $6.61.
A look at the stock’s price movement, the close in the last trading session was $6.81, moving within a range at $6.6 and $6.79. The beta value (5-Year monthly) was 0.91. Turning to its 52-week performance, $7.39 and $2.30 were the 52-week high and 52-week low respectively. Overall, TRVI moved 44.64% over the past month.
Trevi Therapeutics Inc’s market cap currently stands at around $639.07 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-17.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TRVI is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend TRVI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
TRVI’s current price about 23.70% and 45.16% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 72.78, while 7-day volatility ratio is 6.75% and 9.31% in the 30-day chart. Further, Trevi Therapeutics Inc (TRVI) has a beta value of 0.39, and an average true range (ATR) of 0.50. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is 9.23% off current price level while to achieve the yearly target high, price needs to move 9.23%. Nonetheless, investors will most likely welcome a 9.23% jump to $6 which is the analysts’ median price.
If we refocus on Trevi Therapeutics Inc (NASDAQ:TRVI), historical trading data shows that trading volumes averaged 7.54 over the past 10 days and 1.87 million over the past 3 months. The company’s latest data on shares outstanding shows there are 93.60 million shares.
The 40.90% of Trevi Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 49.29% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.79 million on 2025-02-28, giving us a short ratio of 4.54. The data shows that as of 2025-02-28 short interest in Trevi Therapeutics Inc (TRVI) stood at 611.00002 of shares outstanding, with shares short falling to 4.59 million registered in 2025-01-31. Current price change has pushed the stock 60.44% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TRVI stock continues to rise going into the next quarter.
